Download PDF
Aktuelle Dermatologie 2005; 31(8/09): 383-387
DOI: 10.1055/s-2005-861430
Therapiebericht
© Georg Thieme Verlag KG Stuttgart · New York

Therapie der rezidivierenden benignen Aphthosis mit Fumarsäureestern

Treatment of Recurrent Aphtous Ulcers with Fumaric AcidM.  Hagedorn1 , T.  Glaenz1 , E.  Hasche1
  • 1 Hautklinik-Klinikum Darmstadt
Further Information

Publication History





Publication Date:
29 August 2005 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Die rezidivierende benigne Aphthose (RBA) wird epidemiologisch, klinisch und pathogenetisch charakterisiert und drei Subtypen werden differenziert. Die systemische Therapie von 12 RBA-Patienten über einen durchschnittlichen Zeitraum von 17 Monaten mit Fumarsäureestern wird beschrieben und der Nutzen der Behandlung für diese Patienten ausgeführt. Ein Fallbeispiel zeigt die effektive und nebenwirkungsarme Langzeit-Rezidivprophylaxe, die mit Fumarsäureestern bei einer 34-jährigen Patientin mit chronisch rezidivierender Aphthose vom Maior- (Sutton) Typ über bisher 16 Monate erzielt werden konnte. Zu den bekannten immunmodulierenden oder immunsuppressiven Therapieformen der RBA stellen Fumarsäureester in niedriger Dosierung eine viel versprechende, wirksame und gut verträgliche Ergänzung oder Alternative dar.

Abstract

Recurrent aphtous ulcers (RAU) of the oral mucosa show characteristical epidemiologic, clinic and pathogenetic features. Three subtypes can be distinguished. We describe the systemic longterm treatment of 12 RAU patients with fumaric acid and the benefit for them.

Further we present the case of a female RAU patient who, after a different initial treatment, could be protected from recurrency of aphtha by a prophylactic low dose treatment with fumaric acid over 16 months. In addition to established immunomodulating or immunosuppressive therapy of RAU fumaric acid seems to be an effective and well tolerable alternative.

Literatur

  • 1 Albanidou-Farmaki E. et al . HLA-A,B,C and DR antigens in recurrent oral ulcers.  Ann Dent. 1988;  47 5-8
    PubMedSearch in Google Scholar
  • 2 Asadullah K. et al . Influence of monomethylfumarate on monocytic cytokine formation.  ArchDermatolRes. 1997;  289 623-630
    PubMedSearch in Google Scholar
  • 3 Axell T. et al . Association between recurrent aphtous ulcers and tobacco habits.  Scand J Dent Res. 1985;  93 239-242
    PubMedSearch in Google Scholar
  • 4 Brown R S. et al . Combination immunosuppressant and topical steroid therapy for treatment of recurrent major aphthae.  Oral Surg Oral Med Oral Pathol. 1990;  69 (1) 42-44
    CrossrefPubMedSearch in Google Scholar
  • 5 Burton-Kee J E. et al . Different cross-reaction circulating immune complexes in Behçet's syndrome and recurrent oral ulcers.  J Lab Clin Med. 1981;  97 (4) 559-567
    PubMedSearch in Google Scholar
  • 6 Chellemi S J. et al . The association between smoking and aphtous ulcers.  Oral Surg Oral Med Oral Pathol. 1970;  29 832-836
    PubMedSearch in Google Scholar
  • 7 Cooke B ED. Recurrent oral ulcers.  BrJDermatol. 1969;  81 159-161
    PubMedSearch in Google Scholar
  • 8 Crivelli M R. et al . Influence of socioeconomic status on oral mucosa lesion prevalence in school children.  Comm Dent Oral Epidemiol. 1988;  16 58
    PubMedSearch in Google Scholar
  • 9 Dagalis P. et al . Spontaneous migration and chemotactic activity of neutrophil polymorphonuclear leucocytes in recurrent aphthous ulceration.  Oral Surg Oral Med Oral Pathol. 1987;  64 298-301
    CrossrefPubMedSearch in Google Scholar
  • 10 Donatsky O. Comparison of cellular and humoral immunity against streptococcal and adult human oral mucosa antigens in relation to exacerbation of recurrent aphthous stomatitis.  Acta Pathol Microbiol Scand. 1976;  84 (4) 270-282
    PubMedSearch in Google Scholar
  • 11 Fontes V. et al . Recurrent aphthous stomatitis: treatment with colchicine.  Ann Dermatol Venereol. 2002;  129 (12) 1365-1369
    PubMedSearch in Google Scholar
  • 12 From the NIH . Aphtous stomatitis is linked to mechanical injuries, iron and vitamin deficiencies and certain HLA types.  JAMA. 1982;  247 774-775
    CrossrefPubMedSearch in Google Scholar
  • 13 Gallina G. et al . HLA-A, B, C, DR, MT and MB antigen in recurrent aphtous stomatitis.  Oral Surg Oral Med Oral Pathol. 1985;  59 364-370
    CrossrefPubMedSearch in Google Scholar
  • 14 Graykowski E A. et al . Recurrent aphtous stomatitis.  JAMA. 1966;  196 129
    CrossrefPubMedSearch in Google Scholar
  • 15 Graykowsky E A. et al . Summary of workshop on recurrent aphtous stomatitis and Behçet syndrome.  JAmDentAssoc. 1978;  97 599-602
    PubMedSearch in Google Scholar
  • 16 Greenspan J S. et al . Antibody dependent cellular cytotoxicity in recurrent aphtous ulceration.  ClinExpImmunol. 1981;  44 603-610
    PubMedSearch in Google Scholar
  • 17 Höxtermann S. et al . Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.  Dermatology. 1998;  196 223-230
    CrossrefPubMedSearch in Google Scholar
  • 18 Honma T. Electron microscopic study on the pathogenesis of recurrent aphtous ulceration as compared to Behçet's syndrome.  Oral Surg. 1976;  41 (3) 366-377
    CrossrefPubMedSearch in Google Scholar
  • 19 Hornstein O P. Orale Schleimhautaffektionen. In: GW Korting (ed) Dermatologie in Praxis und Klinik. Vol.3. Stuttgart; 1979
    Search in Google Scholar
  • 20 Hutchinson V A. et al . Chronic recurrent aphtous stomatitis.  Mol Biother. 1990;  2 160-164
    PubMedSearch in Google Scholar
  • 21 de Jong R. et al . Selective stimulation of T helper 2 cytokine responses by anti-psoriasis agent monomethylfumarate.  European Journal of Immunology. 1996;  26 2067-2074
    PubMedSearch in Google Scholar
  • 22 Lehner T. et al . The relationship of HLA-B and DR phenotypes to Behçet's syndrome, recurrent oral ulceration and the class of immune complexes.  Immunol. 1982;  47 581-587
    PubMedSearch in Google Scholar
  • 23 Ockenfels H M. et al . The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network.  Br J Dermatol. 1998;  139 390-395
    CrossrefPubMedSearch in Google Scholar
  • 24 Pedersen A. et al . T-lymphocyte subsets in oral mucosa of patients with recurrent aphtous ulceration.  J Oral Pathol Med. 1992;  21 176-180
    PubMedSearch in Google Scholar
  • 25 Porter S R. et al . Aphtous stomatitis.  Clin Exper Dermatol. 1991;  16 235-243
    PubMedSearch in Google Scholar
  • 26 Porter S R. et al . Recurrent aphtous stomatitis: the efficacy of replacement therapy in patients with underlying hematinic deficiencies.  Ann Dent. 1992;  51 14-16
    PubMedSearch in Google Scholar
  • 27 Revuz J. et al . Crossover study of thalidomide vs placebo in severe recurrent aphtous stomatitis.  Arch Dermatol. 1990;  126 923-926
    CrossrefPubMedSearch in Google Scholar
  • 28 Rodu B. et al . Oral mucosal ulcers.  J Am Dent Assoc. 1992;  123 83-86
    PubMedSearch in Google Scholar
  • 29 Rogers R S. et al . Lymphotoxicity in recurrent aphtous stomatitis.  ArchDermatol. 1974;  109 361-363
    PubMedSearch in Google Scholar
  • 30 Rogers R S. Recurrent aphtous stomatitis.  Semin Cutan Med Surg. 1997;  16 278-283
    PubMedSearch in Google Scholar
  • 31 Ruah C B. et al . Treatment of severe recurrent aphthous stomatitis with colchicine.  Arch Otolaryngol Head Neck Surg. 1988;  114 671-675
    PubMedSearch in Google Scholar
  • 32 Savage N W. et al . T-lymphocytes suset changes in recurrent aphtous stomatitis.  Oral Surg Oral Med Oral Pathol. 1985;  60 175-181
    PubMedSearch in Google Scholar
  • 33 Savage N W. et al . The proportion of suppressor-inducer T-lymphocytesis reduced in recurrent aphtous stomatitis.  J Oral Pathol. 1988;  17 293-296
    PubMedSearch in Google Scholar
  • 34 Sebök B. et al . Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in Keratinocyte cultures.  Eur J Pharmacol. 1994;  270 79-87
    PubMedSearch in Google Scholar
  • 35 Shafer W G. et al .A textbook of oral pathology, ed 3. Philadelphia; WB Saunders 1974: 331-344
    Search in Google Scholar
  • 36 Shasky R G. et al . Aphtous ulcers: A difficult clinical entity.  AJOT. 2000;  21 (6) 389-393
    PubMedSearch in Google Scholar
  • 37 Ship J A. Inheritance of aphtous ulcers of the mouth.  J Dent Res. 1965;  44 837-844
    PubMedSearch in Google Scholar
  • 38 Ship J A. Recurrent aphtous stomatitis: an update.  Oral Surg Oral Med Oral Pathol. 1996;  81 141-147
    PubMedSearch in Google Scholar
  • 39 Sircus W. et al . Recurrent aphtous ulceration of the mouth.  Q J Med. 1957;  26 235-249
    PubMedSearch in Google Scholar
  • 40 Sun A. et al . Strong association of HLA-DRw9 in chinese patients with recurrent oral ulcers.  JAMA. 1991;  24 195-198
    PubMedSearch in Google Scholar
  • 41 Sun A. et al . Immunomodulation by levamisole in patients with recurrent aphtous ulcers or oral lichen planus.  J Oral Pathol Med. 1994;  23 (4) 172-177
    PubMedSearch in Google Scholar
  • 42 Sun A. et al . Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of recurrent aphthous ulcerations.  J Oral Pathol Med. 2004;  33 (3) 133-139
    PubMedSearch in Google Scholar
  • 43 Sutton R L. Periadenitis mucosa necrotica recurrens.  J Cutan Dis. 1911;  29 65-71
    PubMedSearch in Google Scholar
  • 44 Taylor L J. et al . Increased production of tumor necrosis factor by peripheric blood leucocytes in patients with recurrent oral aphtous ulceration.  J Oral Pathol Med. 1992;  21 21-25
    PubMedSearch in Google Scholar
  • 45 Thio H B. et al . Long term systemic therapy with dimethylfumarate and monoethylfumarate in psoriasis.  Journal of the EADV. 1995;  4 35-40
    PubMedSearch in Google Scholar
  • 46 Vandermeeren M. et al . Dimethylfumarate is an inhibitor of cytokine-induced VCAM-1, ICAM-1 and E-Selectin expression on human endothelial cells.  Biochem Biophys Res Com. 1997;  234 19-23
    PubMedSearch in Google Scholar
  • 47 Weathers D R. et al . Intraoral ulcerations of recurrent herpes simplex and recurrent aphthae.  JADA. 1970;  81 81-88
    PubMedSearch in Google Scholar

Prof. Dr. med. Manfred Hagedorn

Direktor der Hautklinik Klinikum Darmstadt ·

Heidelberger Landstraße 379 · 64297 Darmstadt